Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New UK Drug Applications At ‘Sustained Levels’ Post-Brexit

MHRA Vaunts ‘Exciting’ New Operating Model

Executive Summary

The MHRA’s chief executive explains to the Pink Sheet how the agency will ensure the UK remains an attractive place to seek approval of new innovative drugs and build on the regulatory flexibilities introduced during the COVID-19 pandemic.

You may also be interested in...

UK Clinical Trial Numbers Still ‘Buoyant’ After Brexit

In this second article on the post-Brexit fortunes of the UK medicines regulator, the MHRA, Pink Sheet looks at the emergence of a new UK clinical trials environment, how the agency is facing up to resource pressures, and when the new fee structure might be ready.

UK’s Early Access To Medicines Scheme To Get New Legal Basis

Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.

UK Industry Warns Against Post-Brexit Regulatory Divergence

The UK must maintain a competitive regulatory framework at home, and its medicines agency should play a part in influencing international regulatory policy alongside other national and global organizations, says a new report from the ABPI.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts